SCHEMBL4964088

SCHEMBL4964088

Cc1c(N)ccc(C(=O)O)c1[N+](=O)[O-]

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.57
ALDH1A1 P00352 4/20 0.57
CYP3A4 P08684 4/20 0.57
ALOX15 P16050 1/20 0.57
TSHR P16473 3/20 0.49
LMNA P02545 1/20 0.45
HNF4A P41235 2/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 4/20 0.41
PKM P14618 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9556010 1.00 TDP1 (0.57) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL2427891 0.91 ALDH1A1 (0.56) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL8671212 0.89 TSHR (0.59) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL3478112 0.89 TSHR (0.59) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL28776906 0.84 TDP1 (0.53) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL3107602 0.84 TSHR (0.50) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL1355836 0.81 TSHR (0.51) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL29561089 0.81 TSHR (0.51) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL11744751 0.81 TDP1 (0.49) TDP1ALDH1A1CYP3A4ALOX15TSHR
SCHEMBL6513444 0.81 TDP1 (0.50) TDP1ALDH1A1CYP3A4ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-08-28 US disclosed
US-5187167-A Antitumor agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-16 US disclosed
US-5081124-A Amino acid and polyamino acid derivatives, inhibitors of thymidylate synthetase IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-01-14 US disclosed
US-4992550-A Thymidylate synthetase inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders LCK, MALT1, MYD88 TDP1 1277/4885ALDH1A1 2293/4885CYP3A4 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.